Arthrosurface Crosses the 30,000 Patient and 100 Publication Milestones

FRANKLIN, Mass., Nov. 28, 2011 /PRNewswire/ -- Arthrosurface, Inc. (www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, announced that it has recently surpassed the 30,000 patient implantation milestone with products having been implanted in Shoulder, Knee, Hip, Toe and Ankle during the last 7 years. The Arthrosurface technology is now available in all 50 states and in more than 25 countries worldwide. In addition to reaching this significant patient milestone a recent global literature review revealed over 100 sources referencing the Arthrosurface HemiCAP^® implants.

Arthrosurface began selling shoulder implants for localized arthritis in the US in 2004 and focal knee implants internationally in 2005. Since then, new products have been added each year to expand its growing list of indications that now number 10 product families with over 150 different implant configurations. While the company believed that its technology would one day become a new standard of care, it also realized that it would eventually require data to support and validate its technology in the conservative orthopaedic marketplace.

Dr. Matthias Schurhoff, MD, VP of Clinical Operations and Scientific Affairs at Arthrosurface, recently commented "We just completed a new worldwide search for all clinical research and related publications on the Arthrosurface technology and the results continue to be extremely positive: Over 100 documented references underline the growing interest for patient specific joint solutions. More than 200 authors and experts in the field of cartilage repair have commented, reported or assessed HemiCAP^® resurfacing in over 60 peer reviewed publications."

The growing body of evidence shows that the positive basic science data is supported by clinical outcomes across the different product groups. The next phase of clinical publications will focus on outcome studies ranging from two to seven years follow-up. At the same time, Arthrosurface is planning to introduce a mix of competitive, new technologies to further complement the surgical spectrum of joint arthrosis and arthritis."

As people live longer, Arthrosurface believes that there is an increasing need for an interim solution prior to total joint surgery. A recent study conducted at Brigham and Women's Hospital, Boston concluded that arthritis is now affecting people earlier in life. The researchers used a validated computer simulation model, called OAPol, to track the number of new knee osteoarthritis cases in the United States in the 1990s and 2010s. They calculated that 7% of Americans older than 45 years have osteoarthritis. The mean age of a patient with osteoarthritis has shifted from 72 years in the 1990s to 56 years today, an average of 16 years earlier in life. The investigators predict 6.5 million new cases of knee osteoarthritis between the ages of 35 to 84 years in the next 10 years. Of those cases, 59% will be in the 45 to 64 year-old age group which is also the fastest growing segment of the overall population based on the recent census.

Arthrosurface boasts that it is perfectly positioned to serve this growing trend in joint disease. With its Focal-to-Total Joint Platform Technology, it offers over 150 different sizes and shapes to effectively cover the damaged area and precisely match the joint contour of each patient.

SOURCE Arthrosurface, Inc.